HeartSciences will appoint Andrea Childs as Chief Executive Officer and Erik Ellingson as Chief Financial Officer, effective at the Closing of a pending merger that increases the board from five to nine members.
| IndividualAndrea ChildsErik EllingsonAndrew SimpsonDanielle Watson | RoleDirector; to be appointed Chief Executive OfficerChief Financial OfficerChief Executive Officer and Chairman (current)Chief Financial Officer (current) | Type of ChangeAppointed (subject to Closing)Appointed (subject to Closing)Replaced as CEO (term restart and amendments to employment agreement)Replaced as CFO | Effective DateEffective as of the Effective Time (Closing)Effective as of the Effective Time (Closing)Employment agreement amended June 22, 2026; term restarts as of ClosingEffective as of the Effective Time (Closing) | ReasonChange in management in connection with pending merger/TransactionsChange in management in connection with pending merger/TransactionsTo lead Parent and legacy business through Closing; retention arrangementsManagement change in connection with pending merger/Transactions | Replacement InfoWill replace Andrew Simpson as CEOWill replace Danielle Watson as CFOWill be replaced by Andrea Childs as CEOWill be replaced by Erik Ellingson as CFO | Background DetailsBiographical details to be included in Proxy StatementBiographical details to be included in Proxy StatementAmendment to employment agreement revises definitions of Just Cause and Constructive Termination; granted 425,000 restricted shares as retention bonus; discretionary cash bonus of $250,000 payable on ClosingApproved discretionary cash bonus of $50,000 (up to $30,000 payable after Parent files Proxy; $20,000 payable at Closing) | Board/Committee Role ChangesTo be elected as director to fill newly created vacancy (Board size increased to nine)Not disclosedExpected to remain on Board after ClosingNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.